A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer

Immune checkpoint agents have not yet been approved for use in advanced prostate cancer. This commentary summarizes the challenges related to this issue, in light of a recently reported case of a patient with DNA mismatch‐repair deficient castration‐resistant prostate cancer who responded to single‐...

Descripción completa

Detalles Bibliográficos
Autor principal: Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459249/
https://www.ncbi.nlm.nih.gov/pubmed/30626711
http://dx.doi.org/10.1634/theoncologist.2018-0819
_version_ 1783410156591120384
author Antonarakis, Emmanuel S.
author_facet Antonarakis, Emmanuel S.
author_sort Antonarakis, Emmanuel S.
collection PubMed
description Immune checkpoint agents have not yet been approved for use in advanced prostate cancer. This commentary summarizes the challenges related to this issue, in light of a recently reported case of a patient with DNA mismatch‐repair deficient castration‐resistant prostate cancer who responded to single‐agent pembrolizumab treatment.
format Online
Article
Text
id pubmed-6459249
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-64592492019-06-20 A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer Antonarakis, Emmanuel S. Oncologist Commentaries Immune checkpoint agents have not yet been approved for use in advanced prostate cancer. This commentary summarizes the challenges related to this issue, in light of a recently reported case of a patient with DNA mismatch‐repair deficient castration‐resistant prostate cancer who responded to single‐agent pembrolizumab treatment. John Wiley & Sons, Inc. 2019-01-09 2019-04 /pmc/articles/PMC6459249/ /pubmed/30626711 http://dx.doi.org/10.1634/theoncologist.2018-0819 Text en © AlphaMed Press 2019
spellingShingle Commentaries
Antonarakis, Emmanuel S.
A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
title A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
title_full A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
title_fullStr A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
title_full_unstemmed A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
title_short A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
title_sort new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459249/
https://www.ncbi.nlm.nih.gov/pubmed/30626711
http://dx.doi.org/10.1634/theoncologist.2018-0819
work_keys_str_mv AT antonarakisemmanuels anewmoleculartaxonomytopredictimmunecheckpointinhibitorsensitivityinprostatecancer
AT antonarakisemmanuels newmoleculartaxonomytopredictimmunecheckpointinhibitorsensitivityinprostatecancer

Ejemplares similares